Aegle Therapeutics Company

Aegle Therapeutics Corporation, a regenerative medicine company isolating extracellular vesicles ("EVs") from allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”).
Technology: Other
Industry: Cell Therapy
Headquarters: Florida, United States
Founded Date: 2013
Investors Number: 25
Total Funding: $175.2M
Estimated Revenue: $1M to $10M
Last Funding Type: Debt Financing

Visit Website
info@aegletherapeutics.com
Register and Claim Ownership